Challenges in IBD Research: Novel Technologies.


Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
16 05 2019
Historique:
received: 29 03 2019
entrez: 17 5 2019
pubmed: 17 5 2019
medline: 2 6 2020
Statut: ppublish

Résumé

Novel technologies is part of five focus areas of the Challenges in IBD research document, which also includes preclinical human IBD mechanisms, environmental triggers, precision medicine and pragmatic clinical research. The Challenges in IBD research document provides a comprehensive overview of current gaps in inflammatory bowel diseases (IBD) research and delivers actionable approaches to address them. It is the result of a multidisciplinary input from scientists, clinicians, patients, and funders, and represents a valuable resource for patient centric research prioritization. In particular, the novel technologies section is focused on prioritizing unmet clinical needs in IBD that will benefit from novel technologies applied to: 1) non-invasive detection and monitoring of active inflammation and assessment of treatment response; 2) mucosal targeted drug delivery systems; and 3) prevention of post-operative septic complications and treatment of fistulizing complications. Proposed approaches include development of multiparametric imaging modalities and biosensors, to enable non invasive or minimally invasive detection of pro-inflammatory signals to monitor disease activity and treatment responses. Additionally, technologies for local drug delivery to control unremitting disease and increase treatment efficacy while decreasing systemic exposure are also proposed. Finally, research on biopolymers and other sealant technologies to promote post-surgical healing; and devices to control anastomotic leakage and prevent post-surgical complications and recurrences are also needed.

Identifiants

pubmed: 31095703
pii: 5490493
doi: 10.1093/ibd/izz077
pmc: PMC6787667
doi:

Substances chimiques

Gastrointestinal Agents 0
Immunosuppressive Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

S24-S30

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK034854
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK056008
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK108648
Pays : United States

Informations de copyright

© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Gut. 2017 Apr;66(4):738-749
pubmed: 28153961
Crit Rev Biomed Eng. 2014;42(1):1-15
pubmed: 25271356
Ultrasound Med Biol. 2018 Apr;44(4):762-770
pubmed: 29331357
Gastroenterology. 1976 Mar;70(3):439-44
pubmed: 1248701
Comput Methods Programs Biomed. 2016 May;128:75-85
pubmed: 27040833
Colorectal Dis. 2016 Jul;18(7):667-75
pubmed: 26921847
J Crohns Colitis. 2016 May;10(5):525-31
pubmed: 26748404
J Clin Invest. 2019 Jan 2;129(1):24-33
pubmed: 30601139
AJR Am J Roentgenol. 2011 Jul;197(1):224-31
pubmed: 21701034
Aliment Pharmacol Ther. 2018 Jan;47(1):6-15
pubmed: 28994131
Ann Surg. 2007 Feb;245(2):254-8
pubmed: 17245179
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
Sci Transl Med. 2016 Nov 16;8(365):365ra157
pubmed: 27856796
Eur J Radiol. 2015 Sep;84(9):1685-93
pubmed: 25851932
Sci Transl Med. 2015 May 6;7(286):286ra68
pubmed: 25947163
N Engl J Med. 2017 Mar 30;376(13):1292-1294
pubmed: 28355498
Gut. 2010 Aug;59(8):1056-65
pubmed: 20525970
Arch Osteoporos. 2015;10:231
pubmed: 26297076
Scand J Gastroenterol. 1999 Jan;34(1):50-4
pubmed: 10048733
Gastroenterol Hepatol (N Y). 2016 Oct;12(10):637-640
pubmed: 27917079
Inflamm Bowel Dis. 2019 May 16;25(Supplement_2):S31-S39
pubmed: 31095701
Gut. 1992 Mar;33(3):331-5
pubmed: 1568651
Biomed Eng Comput Biol. 2014 May 08;6:13-20
pubmed: 25288907
Inflamm Bowel Dis. 2019 May 16;25(Supplement_2):S40-S47
pubmed: 31095704
ACS Sens. 2017 Apr 28;2(4):468-483
pubmed: 28723186
J Crohns Colitis. 2012 Jul;6(6):698-707
pubmed: 22398098
Sci Transl Med. 2015 Aug 12;7(300):300ra128
pubmed: 26268315
Gastroenterology. 2018 Mar;154(4):1172-1194
pubmed: 29329905
Gut. 2005 Feb;54(2):237-41
pubmed: 15647188
Eur Radiol. 2010 Aug;20(8):1945-51
pubmed: 20379822
Gut. 1994 Feb;35(2):231-5
pubmed: 7508411
J Nucl Med. 2017 Jun;58(6):1009-1012
pubmed: 27908970
J Ultrasound Med. 2019 Feb;38(2):271-288
pubmed: 30604884
Gut. 2012 Apr;61(4):622-9
pubmed: 22267595
Theranostics. 2017 Apr 3;7(6):1463-1476
pubmed: 28529630
Inflamm Bowel Dis. 2017 Mar;23(3):421-430
pubmed: 28129289
Clin Cancer Res. 2018 Apr 1;24(7):1574-1585
pubmed: 29301827
Br J Surg. 2015 May;102(6):590-8
pubmed: 25776855
Inflamm Bowel Dis. 2019 May 16;25(Supplement_2):S5-S12
pubmed: 31095706
Inflamm Bowel Dis. 2019 May 16;25(Supplement_2):S13-S23
pubmed: 31095702

Auteurs

Manish Dhyani (M)

Lahey Hospital & Medical Center, Burlington, Massachusetts.

Nitin Joshi (N)

Brigham and Women's Hospital, Boston, Massachusetts.

Willem A Bemelman (WA)

Academic Medical Centre, Amsterdam, Netherlands.

Michael S Gee (MS)

Massachusetts General Hospital, Boston, Massachusetts.

Vijay Yajnik (V)

Takeda Pharmaceutical Company, Boston, Massachusetts.

André D'Hoore (A)

University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium.

Giovanni Traverso (G)

Brigham and Women's Hospital, Harvard Medical School and Massachusetts Institute of Technology, Boston, Massachusetts.

Mark Donowitz (M)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Gustavo Mostoslavsky (G)

Boston University School of Medicine, Boston, Massachusetts.

Timothy K Lu (TK)

Massachusetts Institute of Technology, Cambridge, Massachusetts.

Neil Lineberry (N)

Takeda Pharmaceutical Company, Boston, Massachusetts.

Heiko G Niessen (HG)

Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Dan Peer (D)

School of Molecular Cell Biology and Biotechnology, Tel Aviv University, Tel Aviv, Israel.

Jonathan Braun (J)

Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai, Los Angeles, California.

Conor P Delaney (CP)

Cleveland Clinic Foundation, Cleveland, Ohio.

Marla C Dubinsky (MC)

Icahn School of Medicine at Mount Sinai, New York, New York.

Ashley N Guillory (AN)

University of Texas Medical Branch, Galveston, Texas.

Maria Pereira (M)

Gecko Biomedical, Paris, France.

Nataly Shtraizent (N)

Crohn's & Colitis Foundation, New York, New York.

Gerard Honig (G)

Crohn's & Colitis Foundation, New York, New York.

David Brent Polk (DB)

Department of Biochemistry and Molecular Biology, University of Southern California.
and Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California.

Andrés Hurtado-Lorenzo (A)

Crohn's & Colitis Foundation, New York, New York.

Jeffrey M Karp (JM)

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology, Broad Institute and Harvard Stem Cell Institute, Boston, Massachusetts.

Fabrizio Michelassi (F)

New York-Presbyterian Hospital and Weill Cornell School of Medicine, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH